wd145242, if you consider the current shares issue
Post# of 30066
Posted On: 08/11/2014 12:41:07 AM
wd145242, if you consider the current shares issued and the additional shares already committed as per the prelim proxy filing, then 1 billion shares won't be enough to accomplish what Gerald laid out in his blog.
Refer to my previous post for a rundown on these commitments.
http://investorshangout.com/post/view?id=1815017
Essentially, the company has issued or committed to issue 892.5 million shares of the 1 billion authorized shares. This leaves only 107.5 million shares remaining. This certainly isn't going to be enough to thwart a hostile takeover if some big pharma decides they like the milestone achievements enough to try to acquire the company while still on the OTC.
Currently, the company is valued at $84M so it wouldn't be a stretch to imagine a big pharma company offering $250M ($0.28 per share) now to acquire Amarantus, grabbing rights to the expected $500M/year LymPro revenue stream, with rights to MANF and PhenoGuard as icing on the cake. While company management may reject such an offer, shareholders may be inclined to accept it, especially considering the number of traders in this stock.
While the company has stated they aren't currently aware of any takeover efforts underway, as we get closer to LymPro commercialization, and as MANF RP and Wolframs/Diabetes data becomes available, there may be serious interest. The company could be vulnerable under the current share structure while trading on the OTC at such a low share price. Having additional shares that could be issued to existing shareholders in any takeover attempt would make it significantly more expensive to acquire the company.
Refer to my previous post for a rundown on these commitments.
http://investorshangout.com/post/view?id=1815017
Essentially, the company has issued or committed to issue 892.5 million shares of the 1 billion authorized shares. This leaves only 107.5 million shares remaining. This certainly isn't going to be enough to thwart a hostile takeover if some big pharma decides they like the milestone achievements enough to try to acquire the company while still on the OTC.
Currently, the company is valued at $84M so it wouldn't be a stretch to imagine a big pharma company offering $250M ($0.28 per share) now to acquire Amarantus, grabbing rights to the expected $500M/year LymPro revenue stream, with rights to MANF and PhenoGuard as icing on the cake. While company management may reject such an offer, shareholders may be inclined to accept it, especially considering the number of traders in this stock.
While the company has stated they aren't currently aware of any takeover efforts underway, as we get closer to LymPro commercialization, and as MANF RP and Wolframs/Diabetes data becomes available, there may be serious interest. The company could be vulnerable under the current share structure while trading on the OTC at such a low share price. Having additional shares that could be issued to existing shareholders in any takeover attempt would make it significantly more expensive to acquire the company.
(0)
(0)